CTC Awarded as CRO
It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC), has been awarded as clinical contract resource organisation (CRO) to execute our upcoming phase I study with our lead candidate PN6047. The study is planned to start in the second quarter of 2022 aiming to investigate safety and tolerability in healthy volunteers. This is a study combining a single ascending dose (SAD) part together with a multiple ascending dose (MAD) part under one common protocol. Following a thorough process in which several European CRO:s submitted their proposals for our evaluation, CTC was awarded based on value for money and an excellent audit. CTC is located in Uppsala, Sweden, and has long experience in conducting early phase studies and fulfilled all our expectations as set-out in our Request for Proposals documentation. We look forward to the collaboration with excitement.
CTC Awarded as CRO
It is with pleasure that we can announce that Clinical Trial Consultants AB (CTC), has been awarded as clinical contract resource organisation (CRO) to execute our upcoming phase I study with our lead candidate PN6047. The study is planned to start in the second quarter of 2022 aiming to investigate safety and tolerability in healthy volunteers. This is a study combining a single ascending dose (SAD) part together with a multiple ascending dose (MAD) part under one common protocol. Following a thorough process in which several European CRO:s submitted their proposals for our evaluation, CTC was awarded based on value for money and an excellent audit. CTC is located in Uppsala, Sweden, and has long experience in conducting early phase studies and fulfilled all our expectations as set-out in our Request for Proposals documentation. We look forward to the collaboration with excitement.
Latest news
View all
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more
Meet Bengt von Mentzer, founder and Chief scientific advisor
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read more
Meet Olof Breuer, MD, Clinical pharmacology lead
Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more